| MeSH term | MeSH ID | Detail |
|---|---|---|
| Ileus | D045823 | 3 associated lipids |
| Rectal Diseases | D012002 | 1 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
| Cryan J et al. | FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1719972 |
| Karlsson H et al. | The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. | 1991 | Immunol. Lett. | pmid:1720417 |
| FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
| Christians U et al. | Interactions of FK 506 and cyclosporine metabolism. | 1991 | Transplant. Proc. | pmid:1721280 |
| Wu YM et al. | Interaction between FK 506 and cyclosporine in dogs. | 1991 | Transplant. Proc. | pmid:1721281 |
| Habucky K et al. | The pharmacodynamics of pentobarbital following FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721282 |
| Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
| Andersson J et al. | The effects of FK 506 on cytokine production are dependent on the mode of cell activation. | 1991 | Transplant. Proc. | pmid:1721311 |
| Wang SC et al. | FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. | 1991 | Transplant. Proc. | pmid:1721312 |
| Woo J et al. | Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. | 1991 | Transplant. Proc. | pmid:1721313 |
| McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
| Tzakis AG et al. | FK 506 versus cyclosporine in pediatric liver transplantation. | 1991 | Transplant. Proc. | pmid:1721343 |
| Mieles LA et al. | Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. | 1991 | Transplant. Proc. | pmid:1721344 |
| Nakazato P et al. | Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. | 1991 | Transplant. Proc. | pmid:1721345 |
| Nakamura K et al. | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. | 1991 | Transplant. Proc. | pmid:1721346 |
| de Paulis A et al. | Characterization of the anti-inflammatory effect of FK-506 on human mast cells. | 1991 | J. Immunol. | pmid:1721644 |
| Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
| Lieberman KV et al. | FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). | 1991 | Transplant. Proc. | pmid:1721376 |
| Demetris AJ et al. | Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703360 |
| Ueda D et al. | Influence of FK 506 on renal blood flow. | 1991 | Transplant. Proc. | pmid:1721377 |
| Thomson AW et al. | The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. | 1991 | Transplant. Proc. | pmid:1703361 |
| Perico N et al. | FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. | 1991 | Transplant. Proc. | pmid:1721378 |
| Mieles L et al. | Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1703362 |
| Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
| Warty V et al. | Distribution of FK 506 in plasma lipoproteins in transplant patients. | 1991 | Transplant. Proc. | pmid:1703363 |
| Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
| Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
| Boggs S et al. | FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. | 1991 | Transplant. Proc. | pmid:1721420 |
| Cooper MH et al. | Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. | 1991 | Transplant. Proc. | pmid:1721421 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Michnick SW et al. | Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. | 1991 | Science | pmid:1709301 |
| Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
| Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
| Thomson AW et al. | Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. | 1991 | Transplant. Proc. | pmid:1721452 |
| Sainsbury TS et al. | Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. | 1991 | Transplant. Proc. | pmid:1721453 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Forrest MJ et al. | FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. | 1991 | Biochem. Pharmacol. | pmid:1716098 |
| Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
| Yoshimura R et al. | A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. | 1991 | Transplant. Proc. | pmid:1703686 |
| Miyagawa S et al. | Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. | 1991 | Transplant. Proc. | pmid:1703687 |
| Carroll PB et al. | Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1703688 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |